Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)
Clinical trial NCT00538915 · COMPLETED
Trial details
- NCT number
- NCT00538915
- Sponsor
- ADMA Biologics, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2007-09-01
- Primary completion
- 2009-07-01
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.